Julian Baker’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-2,548,069
Closed -$45.3M 99
2018
Q3
$45.3M Buy
2,548,069
+270,270
+12% +$4.64M 0.3% 28
2018
Q2
$31.4M Hold
2,277,799
0.24% 32
2018
Q1
$20.7M Buy
2,277,799
+1,190,476
+109% +$6.57M 0.18% 43
2017
Q4
$4.65M Buy
+1,087,323
New +$5.18M 0.04% 82
2016
Q4
Sell
-868,983
Closed -$2.69M 138
2016
Q3
$2.69M Sell
868,983
-261,594
-23% -$815K 0.02% 86
2016
Q2
$3.63M Sell
1,130,577
-565,288
-33% -$2.07M 0.04% 79
2016
Q1
$5.26M Hold
1,695,865
0.06% 73
2015
Q4
$6.8M Buy
1,695,865
+339,313
+25% +$1.56M 0.06% 69
2015
Q3
$6.21M Buy
+1,356,552
New +$7.1M 0.06% 74

Other funds holding ECYT

Julian Baker's ECYT Position: Q4 2018 in Review

Julian Baker sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 2,548,069 shares — an estimated $45.3M sold.

Julian Baker first reported a position in ECYT in Q3 2015 and held it in 9 quarters. The position peaked at $45.3M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Julian Baker reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Julian Baker sold 2,548,069 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $45.3M.
  • Julian Baker first reported a position in Endocyte, Inc. Common Stock in Q3 2015 and held it in 9 quarters.
  • Julian Baker's Endocyte, Inc. Common Stock position peaked at $45.3M in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.